Lyell Immunopharma (LYEL) Payables (2020 - 2026)

Lyell Immunopharma has reported Payables for 7 years, with the latest figure at $5.5 million in Q1 2026.

• Quarterly Payables rose 46.67% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 46.67% YoY) and the FY2025 annual result came in at $2.9 million, down 46.09% from the prior year.
• Payables improved to $5.5 million in Q1 2026 per LYEL's latest filing, from $2.9 million in the prior quarter.
• Over five years, Payables peaked at $6.5 million in Q1 2022 and troughed at $2.6 million in Q3 2025.
• A 5-year average of $4.5 million and a median of $4.4 million in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2025 and 2026: Payables sank 46.09% in 2025, then soared 46.67% in 2026.
• Over 5 years, Payables stood at $3.9 million in 2022, then rose by 22.98% to $4.8 million in 2023, then grew by 11.4% to $5.4 million in 2024, then tumbled by 46.09% to $2.9 million in 2025, then surged by 89.01% to $5.5 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $5.5 million, $2.9 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.